Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Latest data and clinical development plans for KB295 in ulcerative colitis (UC) to be presented Call to feature leading experts in UC and Chronic Obstructive Pulmonary Disease (COPD) Company plans to advance both KB295 and KB109 to Phase 2 studies LEXINGTON, Mass., Sept. 29, 2...
LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella ...
--On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter-- --Kaleido and the COPD Foundation to collaborate on the development of KB109 in patients with COPD; plan to initiate Phase 2 clinical s...
LEXINGTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced a strategic collaboration...
LEXINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced the appointment of curren...
LEXINGTON, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CFO William Duke wil...
ChrisChrisW/iStock via Getty Images Goldman Sachs has lowered the rating on Seres Therapeutics (MCRB) to sell from neutral, citing the failure of the company to meet the primary endpoint for ulcerative colitis candidate SER-287 in a mid-stage trial. After losing more than half of market ...
Gainers: ImmunoPrecise Antibodies (IPA) +157%.India Globalization Capital (IGC) +74%.NRx Pharmaceuticals (NRXP) +56%.Universe Pharmaceuticals (UPC) +30%.Summit Wireless Technologies (WISA) +28%.Support.com (SPRT) +25%.Agrify Corporation (AGFY) +20%.PainReform (PRFX) +19%.Resources Connec...
Seres Therapeutics (MCRB) -57% after mid-stage ulcerative colitis study fails main goal.Jupiter Wellness (JUPW) -24% after raises $32.5M capital via stock and warrants offering.TRACON Pharmaceuticals (TCON) -23% after securing $15M capital raise.NETGEAR (NTGR)...
News, Short Squeeze, Breakout and More Instantly...
Kaleido Biosciences Inc. Company Name:
KLDO Stock Symbol:
NYSE Market:
Kaleido Biosciences Inc. Website:
What to Know About Buying Penny Stocks on April 14th, 2022 With another day of trading penny stocks here, there is a lot for investors to consider. Right now, the biggest news came as Elon Musk offered to buy 100% of Twitter Inc. ( NYSE: TWTR ) for $54 per share. Currently, the Tesl...